These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2571729)

  • 1. Resolved 6,7,8,9-tetrahydro-N,N-dimethyl-3H-benz[e]indol-8-amine: central dopamine and serotonin receptor stimulating properties.
    Wikström H; Andersson B; Svensson A; Humber LG; Asselin AA; Svensson K; Ekman A; Carlsson A; Nilsson I; Chidester C
    J Med Chem; 1989 Oct; 32(10):2273-6. PubMed ID: 2571729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and Pharmacology of the enantiomers of the potential atypical antipsychotic agents 5-OMe-BPAT and 5-OMe-(2,6-di-OMe)-BPAT.
    Homan EJ; Copinga S; Unelius L; Jackson DM; Wikström HV; Grol CJ
    Bioorg Med Chem; 1999 Jul; 7(7):1263-71. PubMed ID: 10465402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (R)- and (S)-5,6,7,8-tetrahydro-1-hydroxy-N,N-dipropyl-9H-benzocyclohepten- 8-ylamine. Stereoselective interactions with 5-HT1A receptors in the brain.
    Liu Y; Mellin C; Björk L; Svensson B; Csöregh I; Helander A; Kenne L; Andén NE; Hacksell U
    J Med Chem; 1989 Oct; 32(10):2311-8. PubMed ID: 2795604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. cis-1,2,3a,4,5,9b-hexahydro-3H-benz[e]indoles: synthesis and in vitro binding affinity at dopamine D1 and D2 receptors.
    Cruse SF; Lear J; Klein CL; Andersen PH; Dick RM; Crider AM
    J Pharm Sci; 1993 Mar; 82(3):334-9. PubMed ID: 8095545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurochemical profile of EMD 45609 (carmoxirole), a dopamine DA2-receptor agonist.
    Haase AF; Greiner HE; Seyfried CA
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Jun; 343(6):588-94. PubMed ID: 1682817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships in the 8-amino-6,7,8,9-tetrahydro-3H-benz[e]indole ring system. 1. Effects of substituents in the aromatic system on serotonin and dopamine receptor subtypes.
    Stjernlöf P; Ennis MD; Hansson LO; Hoffman RL; Ghazal NB; Sundell S; Smith MW; Svensson K; Carlsson A; Wikström H
    J Med Chem; 1995 Jun; 38(12):2202-16. PubMed ID: 7783152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Centrally acting serotonergic and dopaminergic agents. 2. Synthesis and structure-activity relationships of 2,3,3a,4,9,9a-hexahydro-1H-benz[f]indole derivatives.
    Lin CH; Haadsma-Svensson SR; Phillips G; Lahti RA; McCall RB; Piercey MF; Schreur PJ; Von Voigtlander PF; Smith MW; Chidester CG
    J Med Chem; 1993 Apr; 36(8):1069-83. PubMed ID: 8097538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug design via pharmacophore identification. Dopaminergic activity of 3H-benz[e]indol-8-amines and their mode of interaction with the dopamine receptor.
    Asselin AA; Humber LG; Voith K; Metcalf G
    J Med Chem; 1986 May; 29(5):648-54. PubMed ID: 3084784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
    Hess EJ; Albers LJ; Le H; Creese I
    J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of a mechanism responsible for potential antidepressant activity of EMD 386088, a 5-HT6 partial agonist in rats.
    Jastrzębska-Więsek M; Siwek A; Partyka A; Antkiewicz-Michaluk L; Michaluk J; Romańska I; Kołaczkowski M; Wesołowska A
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Aug; 389(8):839-49. PubMed ID: 27106213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resolved N,N-dialkylated 2-amino-8-hydroxytetralins: stereoselective interactions with 5-HT1A receptors in the brain.
    Björk L; Höök BB; Nelson DL; Andén NE; Hacksell U
    J Med Chem; 1989 Apr; 32(4):779-83. PubMed ID: 2522991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic and serotonergic activities of imidazoquinolinones and related compounds.
    Moon MW; Morris JK; Heier RF; Chidester CG; Hoffmann WE; Piercey MF; Althaus JS; Von Voigtlander PF; Evans DL; Figur LM
    J Med Chem; 1992 Mar; 35(6):1076-92. PubMed ID: 1348089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907).
    van Vliet LA; Rodenhuis N; Dijkstra D; Wikström H; Pugsley TA; Serpa KA; Meltzer LT; Heffner TG; Wise LD; Lajiness ME; Huff RM; Svensson K; Sundell S; Lundmark M
    J Med Chem; 2000 Jul; 43(15):2871-82. PubMed ID: 10956195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective unilateral inactivation of striatal D1 and D2 dopamine receptor subtypes by EEDQ: turning behavior elicited by D2 dopamine receptor agonists.
    Giorgi O; Biggio G
    Brain Res; 1990 Nov; 533(1):53-9. PubMed ID: 1982234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorescent and biotin probes for dopamine receptors: D1 and D2 receptor affinity and selectivity.
    Madras BK; Canfield DR; Pfaelzer C; Vittimberga FJ; Difiglia M; Aronin N; Bakthavachalam V; Baindur N; Neumeyer JL
    Mol Pharmacol; 1990 Jun; 37(6):833-9. PubMed ID: 2141665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further characterization of structural requirements for agonists at the striatal dopamine D2 receptor and a comparison with those at the striatal dopamine D1 receptor. Studies with a series of monohydroxyaminotetralins on acetylcholine release from rat striatum.
    Seiler MP; Markstein R
    Mol Pharmacol; 1984 Nov; 26(3):452-7. PubMed ID: 6238231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationships in the 8-amino-6,7,8,9-tetrahydro-3H-benz[e]indole ring system. 2. Effects of 8-amino nitrogen substitution on serotonin receptor binding and pharmacology.
    Ennis MD; Stjernlöf P; Hoffman RL; Ghazal NB; Smith MW; Svensson K; Wikström H; Haadsma-Svensson SR; Lin CH
    J Med Chem; 1995 Jun; 38(12):2217-30. PubMed ID: 7783153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist.
    Knoerzer TA; Nichols DE; Brewster WK; Watts VJ; Mottola D; Mailman RB
    J Med Chem; 1994 Jul; 37(15):2453-60. PubMed ID: 7914538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute reserpine treatment induces down regulation of D-1 dopamine receptor associated adenylyl cyclase activity in rat striatum.
    Thomas KL; Rose S; Jenner P; Marsden CD
    Biochem Pharmacol; 1992 Jul; 44(1):83-91. PubMed ID: 1321631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropharmacological profile of a new series of dopamine agonists: N-n-propyl-hexahydronaphthoxazines.
    Hazelhoff B; De Vries JB; Dijkstra D; Mulder TB; Timmermans PB; Wynberg H; Horn AS
    Eur J Pharmacol; 1986 May; 124(1-2):93-106. PubMed ID: 3720849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.